Oncology · ChemotherapyRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Azacitidine ANDA204949 by Pharmobedient

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:32:11 AM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Pharmobedient's ANDA for Azacitidine signifies a shift in the competitive landscape for oncology therapies. This generic entry could pressure pricing and market share for existing branded products, necessitating strategic adjustments from current market players. Regulatory context from FDA (FDA AP — AZACITIDINE (SUPPL)) supports the near-term read. Assessment grounded in 28 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on pricing and market share of current Azacitidine products. The strongest clinical anchor is Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 8 regulatory and 4 competitive items passed relevance filtering for Pharmobedient.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for Welireg Supplement from Merck. This approval could enable Pharmobedient to enter the market with a generic version of Azacitidine, increasing competition against existing branded therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AZACITIDINE (SUPPL) (FDA). Entity match (pharmobedient); Regulatory pathway relevance (nda). The approval of the ANDA indicates a successful regulatory pathway for Pharmobedient, which may influence future submissions and approvals in the oncology space.

Key Risks

Elevated medium regulatory exposure for Pharmobedient could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on Pharmobedient through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The introduction of a generic version of Azacitidine may lead to reduced prices and increased competition, potentially impacting revenue for existing branded therapies.
Upside for Pharmobedient may improve if Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Pharmobedient may improve if Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. (PubMed) delivers favorable follow-through.
Upside for Pharmobedient may improve if Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of this generic entry on pricing and market share of current Azacitidine products.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for market entry and any potential pricing strategies from Pharmobedient.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AZACITIDINE (SUPPL)
FDAhigh relevance
Entity match (pharmobedient); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (pharmobedient); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHESGO (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRETINOIN (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ENSPRYNG (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ASk Questions in GYnecologic Oncology (ASQ-GYO)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Welireg Supplement from Merck
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Grants Approval for Gallium Ga-68 Gozetotide (ANDA216410)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Thalidomide ANDA213267 by NATCO
Humanexa Signalsmedium relevance
Moderate corpus alignment

Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The regulatory roles of non-coding RNAs in aerobic glycolysis and therapeutic potential in pancreatic ductal adenocarcinoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Diagnostic and prognostic value of lncSPATA8-AS1 in prostate cancer and its regulatory effect on tumor progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pharmobedient
Azacitidine

Commercial impact

medium

The introduction of a generic version of Azacitidine may lead to reduced prices and increased competition, potentially impacting revenue for existing branded therapies.

Regulatory impact

medium

The approval of the ANDA indicates a successful regulatory pathway for Pharmobedient, which may influence future submissions and approvals in the oncology space.

What to watch

Monitor the timeline for market entry and any potential pricing strategies from Pharmobedient.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.